Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals trailed consensus on adjusted EPS but topped revenue expectations in the second fiscal quarter of 2026, reported August 3, 2026, as revenue rose 15.5% to about $1.2 billion, driven by its marketed medicines across sleep disorders, epilepsy, and oncology. On the scorecard versus estimates, adjusted EPS of $5.71 trailed the $6.18 estimate (-7.6%), while revenue of $1.208 billion topped the $1.114 billion estimate (+8.4%). Net income came in at roughly $192.8 million, improving from a net loss of about $718.5 million a year ago, alongside a revenue lift from about $1.0 billion in the year-ago quarter. Profitability stayed high, with gross profit of about $1.1 billion translating to a gross margin of roughly 90%, and operating income of about $248.2 million for an operating margin near 21%. The quarter also generated operating cash flow of roughly $415.7 million. For the next period, consensus calls for EPS of $6.49 on revenue of $1.210 billion.